cyproterone and Pancreatic-Neoplasms

In a prospective controlled clinical trial, 108 patients with pancreatic adenocarcinoma were randomly allocated to receive tamoxifen 20 mg b.d., cyproteron acetate 100 mg t.d.s. or no active treatment. The median survival of those receiving tamoxifen was longer than either of the other two groups (5.25 compared to 4.25 and 3 months, respectively) but this difference did not achieve statistical significance. Cox regression analysis of 12 clinical and biochemical features showed that, for the entire group of patients, survival was significantly longer in younger patients, those undergoing surgical bypass and those with better initial performance status. However, even when adjustment was made to allow for the distribution of these prognostic variables within the three groups, the difference in survival still did not achieve statistical significance. No side-effects attributable to treatment was observed.

Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Cyproterone; Cyproterone Acetate; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Tamoxifen

The results of a previous 4-mo study in azaserine-treated rats and BOP-treated hamsters indicated that orchiectomy inhibited pancreatic growth and development of putative preneoplastic lesions in the exocrine pancreas of rats but not hamsters. This 12-mo study was carried out to investigate the effects of orchiectomy, alone and in combination with testosterone, and of treatment with cyproterone acetate on pancreatic carcinogenesis in azaserine-treated rats and BOP-treated hamsters. Treatment started 4 mo after injection of the carcinogen. In orchiectomized rats, pancreatic wt was lower than in controls, whereas pancreatic wt of orchiectomized rats treated with testosterone was similar to that of controls. Both orchiectomy and cyproterone acetate caused a decrease in body wt gain and had an inhibitory effect on pancreatic carcinogenesis. Testosterone treatment did not influence the inhibitory effects of orchiectomy on body wt gain and on pancreatic carcinogenesis. In hamsters, neither orchiectomy, alone or in combination with testosterone, nor cyproterone acetate (CA) affected pancreatic growth or pancreatic carcinogenesis. This study indicates that testosterone plays a minor role in the development of pancreatic tumors induced in rats by azaserine but not in that of pancreatic tumors induced in hamsters by BOP.

Topics: Animals; Azaserine; Body Weight; Cricetinae; Cyproterone; Cyproterone Acetate; Growth Substances; Male; Mesocricetus; Nitrosamines; Orchiectomy; Organ Size; Pancreas; Pancreatic Neoplasms; Rats; Rats, Inbred Strains; Specific Pathogen-Free Organisms; Testosterone

Topics: Adenocarcinoma; Aminoglutethimide; Animals; Cyproterone; Hormones; Humans; Hydrocortisone; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Tamoxifen; Testosterone; Transplantation, Heterologous